Our top pick for
Building a portfolio
Opthea Limited is a biotechnology business based in the US. Opthea shares (OPT) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||USD$8.45 - USD$18.0624|
|50-day moving average||USD$9.6766|
|200-day moving average||USD$11.5151|
|Wall St. target price||USD$36.92|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-393,700|
|Return on assets TTM||-16.98%|
|Return on equity TTM||-32.37%|
|Market capitalisation||USD$379.8 million|
TTM: trailing 12 months
There are currently 64,255 Opthea shares held short by investors – that's known as Opthea's "short interest". This figure is 15.5% down from 76,078 last month.
There are a few different ways that this level of interest in shorting Opthea shares can be evaluated.
Opthea's "short interest ratio" (SIR) is the quantity of Opthea shares currently shorted divided by the average quantity of Opthea shares traded daily (recently around 10215.421303657). Opthea's SIR currently stands at 6.29. In other words for every 100,000 Opthea shares traded daily on the market, roughly 6290 shares are currently held short.
To gain some more context, you can compare Opthea's short interest ratio against those of similar companies.
However Opthea's short interest can also be evaluated against the total number of Opthea shares, or, against the total number of tradable Opthea shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Opthea's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Opthea shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Opthea shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Opthea.
Find out more about how you can short Opthea stock.
We're not expecting Opthea to pay a dividend over the next 12 months.
Over the last 12 months, Opthea's shares have ranged in value from as little as $8.45 up to $18.0624. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Opthea's is -0.0183. This would suggest that Opthea's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Opthea has bucked the trend.
To put Opthea's beta into context you can compare it against those of similar companies.
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. .
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.